ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., December 06, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from ...

Rusfertide maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks in the VERIFY study. Patients switching from placebo to rusfertide showed rapid ...

Patients with polycythemia vera (PV) taking the investigational therapy rusfertide were able to largely maintain hematocrit control and avoid the need for phlebotomy over 52 weeks, according to ...

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit ...

Evaluation in 18 patients with polycythemia vera showed hematocrit control below 45%, accompanied by a "dramatic decrease in ...

A 27-year-old man faces animal cruelty charges after a traffic stop revealed a malnourished dog in his car. The dog, Sprout, ...

This article was reviewed by Felix Gussone, MD. How to Read Blood Test Results: What “Normal” Really Means for Your Health ...

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well ...

(Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, announced today that a leading Northeastern U.S. children’s hospital has ...

Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs December 7, 2025 ...